Senores Pharmaceuticals IPO

Serving Regulated Markets: Company manufactures products for the Regulated Markets through its US FDA-approved facility at Atlanta, US which has a strong regulatory track record and has been approved by the US FDA.

Niche product portfolio : In Regulated Markets, company targets niche and difficult-to-manufacture complex products which have market potential in the small to mid-market range. In these markets, prominent global pharmaceutical companies are not present and the competition is less.

Long-term marketing arrangements: Company has entered into long-term marketing arrangements with major generic pharma and marketing companies in the Regulated Markets including Lannett Company Inc., Prasco LLC, Jubilant Cadista Pharmaceuticals Inc., Sun Pharmaceuticals Industries Limited, Cintex Services LLC and Dr. Reddy’s Laboratories Inc.

Presence in the Emerging Markets: Company has an established presence in Emerging Markets and currently marketing its products in 43 countries with focus on Latin America, Africa, Commonwealth of Independent States, South-East Asia and Middle East regions.

Strong R&D capabilities : They have a formulation development laboratory at its Atlanta Facility which acts as its front-end R&D center supported by a back-end R&D in India.

Partner & DIstributor dependence: Company's business is depends on sale of products through third party marketing partners and distributors. The loss of marketing partners or distributors could adversely affect business.

Stringent Quality requiremnts: Company is subject to strict technical specifications, quality requirements, and regular audits by its customers. Any failure to comply with the quality standards and technical specifications may lead to loss of business.

Highly regulated industry: Company operates in a highly regulated industry. The development, testing, manufacturing, marketing and sale of pharma products are subject to extensive regulation in India, the US and other countries where they export.